Holen Sie sich die Stockscreener-App
9.21
0.44%
0.04
Schlusskurs vom Vortag:
$9.17
Offen:
$9.23
24-Stunden-Volumen:
1.37M
Relative Volume:
0.48
Marktkapitalisierung:
$1.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-294.51M
KGV:
-2.5871
EPS:
-3.56
Netto-Cashflow:
$-244.42M
1W Leistung:
+11.23%
1M Leistung:
-10.76%
6M Leistung:
-34.73%
1J Leistung:
-78.68%
1-Tages-Spanne:
$9.13
$9.38
1-Wochen-Bereich:
$8.635
$9.83
52-Wochen-Spanne:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.21 | 1.17B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - WV News
Dyne Therapeutics Inc. Stock Analysis and ForecastMassive profits - jammulinksnews.com
What analysts say about Dyne Therapeutics Inc. stockDynamic profit opportunities - printweek.in
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance
Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus
Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
(DYN) Trading Report - news.stocktradersdaily.com
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ATTENTION DYN Shareholders: Lost Money on Dyne Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Petri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debt - The Business Journals
Dyne Therapeutics Announces Closing of Public Offering of Common - GuruFocus
Dyne Therapeutics' $230M Capital Injection: A Strategic Gamble in Rare Neuromuscular Disorders? - AInvest
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $230 Million Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Closing of Public Offering of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect - ACCESS Newswire
Shareholders Alert: Investigation Into Dyne Therapeutics, Inc. (DYN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Dyne Therapeutics (DYN) Launches $200 Million Public Offering - GuruFocus
Dyne Therapeutics slides on $200 mln equity raise - TradingView
Dyne Therapeutics, Inc. (DYN) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Dyne Therapeutics' $200M Stock Offering: Strategic Necessity or Shareholder Dilution? - AInvest
Fraud Investigation: Levi & Korsinsky Investigates Dyne Therapeutics, Inc. (DYN) on Behalf of Shareholders - ACCESS Newswire
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - 富途牛牛
Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr - Nasdaq
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital - citybiz
Dyne Therapeutics Announces Proposed Public Offering of Common S - GuruFocus
Dyne Therapeutics stock falls after announcing $200 million share offering By Investing.com - Investing.com South Africa
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):